Account Manager - Special Care
About the job
- Several years of experience in specialist physician field sales for prescription medicines.
- Authorization as a pharmaceutical representative under Section 75 of the German Medicinal Products Act.
- Knowledge of pharmacology in the relevant therapeutic areas, currently neurology and gastroenterology.
- Customer orientation, professional stakeholder management, and the ability to establish long-term relationships.
- Strong sales competence, scientific argumentation skills, and a results-oriented approach.
- Analytical and entrepreneurial thinking, including confident interpretation of regional market and healthcare data.
- High self-organization, digital competence, and a structured working method.
- A valid Class B driver's license.
- Residence in the territory being supported.
- Plan, prepare, and independently conduct indication-related scientific discussions and visits with practicing specialist physicians to provide information about assigned products in pain, neurology, and gastroenterology.
- Achieve growth and sales targets for the relevant products and portfolio.
- Identify and strategically manage relevant customer groups, specialist physicians, specialized centers, and selected outpatient clinics.
- Build and maintain relationships with regional and national key opinion leaders in compliance with legal requirements and internal codes and rules.
- Analyze and actively shape regional networks that influence prescribing behavior among relevant target groups.
- Provide evidence-based, indication-specific advice on products, services, and treatment options in the defined territory.
- Implement the applicable marketing and sales strategy for the territory, including use of discussion materials, relevant study content, competitor information, and individualized action planning based on customer relationship management and market data.
- Actively support treatment switches and new treatment initiations and ensure stable patient support.
- Serve as a competent, scientifically grounded contact for specialist physicians to strengthen Viatris brands.
- Plan, conduct, and/or support regional and national scientific events in accordance with compliance and internal requirements.
- Document all activities, sample distribution, and customer data promptly and completely in the customer relationship management system, currently Veeva/Salesforce.com.
- Report adverse drug reactions within 24 hours in accordance with applicable legal and internal regulations.
- Perform administrative tasks such as expense reports and reimbursements.
- A degree in natural sciences or a medical-pharmaceutical background.
- Good English skills for using international study and product information and facilitating internal company communication.
About the company
Viatris provides access to medicines worldwide with a portfolio of branded drugs, generics, complex generics, and biosimilars across 165+ countries. Medicines are manufactured and distributed through its global supply chain and commercial network, serving cardiovascular, infectious diseases, immunology, and oncology. It leverages the legacy of Mylan and Upjohn to grow through both expanding its existing products and pursuing partnerships and acquisitions, driven by its broad portfolio and international reach. The goal is to improve patient health by expanding access to affordable medicines while pursuing sustainable operations and addressing public health challenges like non-communicable diseases.
Company Size
10,001+
Company Stage
IPO
Headquarters
Canonsburg, Pennsylvania
Founded
1961
Get referred to Viatris
See people who can refer or advise you
Simplify's Take
What believers are saying
- Second-quarter 2026 revenue rose 5% to $3.8 billion, and guidance increased.
- Debt fell after $900 million repayment, reducing gross leverage to 2.9x.
- Tyrvaya divestiture, Gwyn Lo, and meloxicam NDA support a higher-value portfolio shift.
What critics are saying
- Nashik fire and FDA Form 483 disruptions cut second-half 2026 revenue by $100-$150 million.
- Greater China procurement changes pressure hospital volumes, squeezing one of Viatris's fastest growth engines.
- Generic pricing MDL and ongoing patent fights in Japan keep legal overhangs persistent.
What makes Viatris unique
- Viatris pairs 165-country reach with complex generics, branded drugs, and biosimilars.
- Japan approved WAKIX on September 16, 2026, expanding first-in-class sleep medicine reach.
- FDA approved Gwyn Lo on July 29, 2026, adding a differentiated women’s health product.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Life Insurance
401(k) Retirement Plan
401(k) Company Match
Wellness Program
Paid Holidays
Growth & Insights and Company News
6 month growth
18%1 year growth
18%2 year growth
18%The South Jordan Journal is the local newspaper covering news and events in the City of South Jordan, Utah. The South Jordan Journal provides one of the best advertising channels to the residents of the City of South Jordan.
Viatris Inc., a global pharmaceutical company based in Canonsburg, Pennsylvania, has significantly outperformed the S&P 500. The stock surged 8.7% over the past three months, compared to the index's 4.7% gain. Year to date, shares climbed 37.5%, whilst the S&P 500 rose 12.6%. With a market cap of $10.4 billion, Viatris operates in 165+ countries and covers more than 10 major therapeutic areas. The company sells more than 80 billion doses annually across 1,400 approved molecules. On 16 September, shares jumped 2.2% after Japan approved WAKIX for treating excessive daytime sleepiness. The company's strong performance stems from improved business momentum, solid cash generation, and progress in its higher-value product portfolio.
Viatris has received approval from Japan's Ministry of Health, Labour and Welfare for WAKIX (pitolisant) to treat excessive daytime sleepiness associated with obstructive sleep apnea syndrome and narcolepsy. WAKIX is the first histamine H3 receptor antagonist/inverse agonist approved in Japan for these conditions. The treatment addresses excessive daytime sleepiness, a symptom affecting both conditions that can significantly impact daily functioning and quality of life. WAKIX is not classified as a controlled substance and has been designated an orphan drug in Japan for narcolepsy. The approval was supported by positive data from domestic Phase 3 clinical trials in Japan and international studies. WAKIX, discovered by Bioprojet and licensed to Viatris for Japan, has previously received approvals in more than 38 countries for narcolepsy.
Viatris reported strong Q2 2026 results, with total revenues of $3.8 billion, representing 3.5% operational growth year-over-year. The pharmaceutical company posted adjusted EBITDA of $1.2 billion and adjusted earnings per share of $0.69. CEO Scott Smith highlighted strong commercial performance across the company's global portfolio, particularly in Greater China where investments in established brands drove meaningful growth. North America also saw solid growth from complex generics and transdermal products. The company announced US regulatory approval for Gwyn Lo last week, with a launch planned for later this year. Fast-acting meloxicam continues through FDA review, with launch preparations underway. Based on the strong quarterly performance, Viatris raised its outlook for the remainder of 2026. The results exceeded company expectations and demonstrated continued improvement in operating leverage.
Viatris reported second-quarter revenue of $3.76 billion, up 4.9% year-on-year and beating analyst estimates of $3.68 billion. The medication company's non-GAAP earnings per share of $0.69 exceeded forecasts by 15%. CEO Scott Smith attributed the performance to strong commercial execution in Greater China, where investments in established brands and e-commerce drove double-digit growth. Demand for cardiovascular products and higher-margin generics in North America also contributed. The company raised its full-year adjusted EPS guidance to $2.52 at the midpoint, a 5% increase, whilst lifting revenue guidance slightly to $14.75 billion. However, operating margin fell to 0.2% from 6.5% in the prior-year quarter. Management noted supply chain disruptions and lower-margin products in emerging markets as headwinds, alongside manufacturing challenges and policy changes in China.